Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst
Cytokinetics receives a Buy rating from Stifel, with a promising outlook for aficamten in the $3 billion U.S. oHCM market, ...
Cytokinetics started at buy by Stifel, aficamten highlighted
Stifel has initiated coverage of Cytokinetics (CYTK) with a buy rating, citing its drug aficamten, valuation and upcoming ...
Royalty Pharma simplifies corporate structure with $1.1 billion deal
Founded by Mexican billionaire and former Lazard banker Pablo Legorreta, the firm buys royalties on potential blockbuster drugs from academic labs and biotechnology companies, which in turn use the ...
Aficamten Poised for Best-in-Class Status in oHCM Treatment with Anticipated Phase 3 Data and Promising Trial Results
Analyst Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Cytokinetics (CYTK – Research Report) and keeping the price target at ...
Yahoo Finance14d
Royalty Pharma to Highlight Accomplishments and Provide Business Update at 43rd Annual J.P. Morgan Healthcare Conference
Royalty Pharma to benefit from new product launches in 2025, including Servier’s Voranigo, Bristol Myers Squibb’s Cobenfy, Ascendis’ Yorvipath, Syndax and Incyte’s Niktimvo and Geron’s ...
Investing16d
Cytokinetics’ SWOT analysis: aficamten progress boosts stock outlook
The company’s lead candidate, aficamten, has been advancing steadily through the regulatory process. Cytokinetics is on track to complete its New Drug Application (NDA) submission to the U.S. Food and ...